PRNewsWire
16 Jun 2026, 20:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Elicio Therapeutics' Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet its primary disease-free survival endpoint in pancreatic cancer. — The failure of a lead clinical pipeline candidate typically leads to a massive loss of company valuation and destroys the primary growth thesis for biotech investors.
-1.00Elicio Therapeutics reported Q1 2026 results with zero revenue and a widening net loss. — Lack of revenue combined with increasing R&D burn indicates a high dependency on clinical success for survival, increasing the risk profile.
-0.60Law firm SueWallSt has initiated an investigation into Elicio Therapeutics' officers and directors for potentially misleading statements regarding the AMPLIFY-7P program. — The threat of securities litigation adds legal overhead and regulatory risk to an already distressed company.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company's lead clinical program failed its primary endpoint, shares collapsed by over 72%, and it reported zero revenue with widening losses.
Shares dropped 17% after the company cut its FY 2026 revenue guidance.
Investors lost over 10% of holdings following a gap revealed in the Q4 FY 2026 earnings release.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
